Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Diagnostics
In Vitro Diagnostics
Return to: MDBR Home | Diagnostics | In Vitro Diagnostics

Meridian Bioscience launches TruQuick rapid tests for Asia Pacific markets

MDBR Staff Writer Published 06 February 2017

Meridian Bioscience has introduced TruQuick rapid tests for Asia Pacific and other emerging markets.

TruQuick includes point-of-care rapid tests, which will be used to diagnose tropical, infectious, sexually transmitted, respiratory, gastrointestinal, cancer, and cardiac diseases.

According to the company, TruQuick is a qualitative lateral flow chromatographic immunoassay menu of over 60 products.

The tests will enable to diagnose pathogens and other important acute diseases in 10 to 20 minutes with accuracy and speed.

Meridian Asia Pacific president Dr Lourdes Weltzien said: “We are excited to launch the new TruQuick brand of rapid tests for the rapidly growing point-of-care market in the Asia Pacific region.

“As for other regions of the world, Meridian will quickly introduce the TruQuick brand of products based on regional demands and registration priorities.”

Meridian Bioscience chief commercial officer and president Richard Eberly said: “One of Meridian’s key strategies over the past few years has been to expand our global commercial operations in emerging markets around the world.”

Meridian develops and produces a range of diagnostic test kits, rare reagents, specialty biologicals and components.

The firm’s diagnostic tests can be used in the early diagnosis and treatment of common medical conditions such as infections and lead poisoning.

In addition, the firm supplies rare reagents, specialty biologicals and components for organizations in the life science and agribio industries.